ISSN: 7027-2221

Author : M. Ghareeb, Mowafaq

l Comparative bioavailability (bioequivalence) of a newly developed formula of Clopidogrel against Actavis tablets in fasting healthy male adult Iraqi subjects

Mowafaq M. Ghareeb

karbala journal of pharmaceutical sciences, Volume 8, Issue 13, Pages 49-58

Objective: The study was performed to compare the bioavailability (bioequivalence) of a newly developed generic formula of clopidogrel 75 mg tablet as a test product against Actavis tablet containing 75 mg clopidogrel as the reference formula.
Methods: The newly developed generic formula of clopidogrel tablet was prepared using co-processed excipients composed mainly of microcrystalline cellulose, superdisintegrant, glidant, and magnesium stearate. In vitro dissolution test was done first to compare the test to the reference formulas, followed by the in vivo study. Both drug products were administered to 40 Iraqi male healthy adult subjects under fasting state applying randomized, two periods, two sequences, two-way crossover design with one week washout period between dosing. Blood samples were obtained over 72 hours interval from each subject, and the concentrations of the inactive metabolite of clopidogrel (clopidogrel carboxylic acid) were determined in serum by LC-MS/MS method. From serum concentration versus time data of each subject, the pharmacokinetics parameters AUC0-t, AUC0-infinity, Cmax, Tmax, and T0.5 were calculated applying non-compartmental data analysis.
Results: The dissolution profile of the test product was found to be similar to the reference product with similarity factor (f2) equal to 79.4%. The geometric mean ratios of the primary pharmacokinetic parameters used for bioequivalence testing of the test/reference products were; 102.47% for AUC0-t, 102.68% for AUC0-infinity and 101.85% for Cmax. The 90% confidence intervals for AUC0-t, AUC0-infinity and Cmax were 93.46-109.18 %, 98.78-108.32% and 91.65-104.33%, respectively. Since the 90% confidence intervals for these parameters were within the 80–125% interval proposed by FDA, it was concluded that the newly developed clopidogrel 75 mg tablet was bioequivalent to the reference product produced by Actavis in term of both the rate and extent of absorption and bioavailability. Consequently, the newly developed clopidogrel 75 mg tablet is interchangeable with clopidogrel 75 mg tablet manufactured by Actavis and can be prescribed as an alternative in the Iraqi market.